DrugPatentWatch Database Preview
FETZIMA Drug Profile
Which patents cover Fetzima, and when can generic versions of Fetzima launch?
Fetzima is a drug marketed by Allergan Sales Llc and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-four patent family members in twenty-seven countries.
The generic ingredient in FETZIMA is levomilnacipran hydrochloride. There are ten drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the levomilnacipran hydrochloride profile page.
Summary for FETZIMA
| International Patents: | 54 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 51 |
| Clinical Trials: | 5 |
| Patent Applications: | 33 |
| Drug Prices: | Drug price information for FETZIMA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for FETZIMA |
| DailyMed Link: | FETZIMA at DailyMed |
Generic Entry Opportunity Date for FETZIMA
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for FETZIMA
| Drug Class | Serotonin and Norepinephrine Reuptake Inhibitor |
| Mechanism of Action | Norepinephrine Uptake Inhibitors Serotonin Uptake Inhibitors |
Synonyms for FETZIMA
| (+)-(1S,2R)-MILNACIPRAN |
| (+)-Milnacipran |
| (1R,2S)-rel-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide hydrochloride |
| (1R,2S)-rel-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide monohydrochloride |
| (1S-cis)-Milnacipran Hydrochloride |
| (1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide |
| (1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide hydrochloride |
| (1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide;hydrochloride |
| (1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide |
| (1S,2R)-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide Hydrochloride |
| (1S,2R)-2-Aminomethyl-1-phenyl-cyclopropanecarboxylic acid diethylamide |
| (1S,2R)-milnacipran |
| (1S,2R)-Milnacipran Hydrochloride |
| 101152-94-7 |
| 152M947 |
| 175131-60-9 |
| 371U2ZK31U |
| 96847-54-0 |
| AC1OCEN6 |
| AC1OCEN8 |
| AK481450 |
| AKOS025311514 |
| API0003393 |
| AS-12868 |
| AT-28508 |
| BDBM50032379 |
| C15H22N2O.HCl |
| CCG-231710 |
| CHEBI:136040 |
| CHEMBL2105732 |
| CHEMBL99946 |
| cis-(+)-Milnacipran Hydrochloride |
| cis-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide Hydrochloride |
| CS-4972 |
| Cyclopropanecarboxamide, 2-(aminomethyl)-N,N-diethyl-1-phenyl-, (1S,2R)- |
| D02XOK |
| D10072 |
| D10133 |
| Dalcipran |
| DB08918 |
| F 2695 |
| F 2695 hydrochloride |
| F-2207 |
| F-2695 |
| f2-695 |
| F2695 |
| Fetzima (TN) |
| GJJFMKBJSRMPLA-DZGCQCFKSA-N |
| GTPL7435 |
| HY-B0168B |
| Ixel |
| J10386 |
| Joncia |
| K-0218 |
| Levomilnacipran |
| Levomilnacipran (USAN/INN) |
| Levomilnacipran [USAN:INN] |
| Levomilnacipran HCl |
| LEVOMILNACIPRAN HYDROCHLORIDE |
| Levomilnacipran hydrochloride (USAN) |
| Levomilnacipran hydrochloride [USAN] |
| M2133 |
| MFCD00901293 |
| MFCD18433402 |
| Midalcipran hydrochloride |
| Milnacipram |
| Milnacipran ((1S-cis) hydrochloride) |
| Milnacipran (1S-cis) hydrochloride |
| Milnacipran HCl |
| Milnacipran hydrochloride |
| Milnacipran Hydrochloride 1.0 mg/ml in Methanol (as free base) |
| MolPort-019-939-251 |
| Savella |
| SCHEMBL1148742 |
| SCHEMBL1414867 |
| TN-912 |
| Toledomin |
| UGM0326TXX |
| UNII-371U2ZK31U |
| UNII-G56VK1HF36 component GJJFMKBJSRMPLA-DZGCQCFKSA-N |
| UNII-RNZ43O5WW5 component XNCDYJFPRPDERF-NQQJLSKUSA-N |
| UNII-UGM0326TXX |
| ZINC506 |
US Patents and Regulatory Information for FETZIMA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergan Sales Llc | FETZIMA | levomilnacipran hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 204168-001 | Jul 25, 2013 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Allergan Sales Llc | FETZIMA | levomilnacipran hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 204168-002 | Jul 25, 2013 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Allergan Sales Llc | FETZIMA | levomilnacipran hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 204168-001 | Jul 25, 2013 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Allergan Sales Llc | FETZIMA | levomilnacipran hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 204168-003 | Jul 25, 2013 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Allergan Sales Llc | FETZIMA | levomilnacipran hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 204168-002 | Jul 25, 2013 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Allergan Sales Llc | FETZIMA | levomilnacipran hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 204168-004 | Jul 25, 2013 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Paragraph IV (Patent) Challenges for FETZIMA
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Capsules | 20 mg, 40 mg, 80 mg and 120 mg | ➤ Subscribe | ➤ Sign Up |
International Patents for FETZIMA
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Japan | 2013510176 | ➤ Sign Up |
| Japan | 2013517290 | ➤ Sign Up |
| Japan | 2010090143 | ➤ Sign Up |
| European Patent Office | 2536688 | ➤ Sign Up |
| World Intellectual Property Organization (WIPO) | 2011057176 | ➤ Sign Up |
| Poland | 219671 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
